NCT02217527View on ClinicalTrials.gov

Test of Novel Drug for Smoking Cessation

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

January 31, 2018

Conditions
Smoking Cessation
Interventions
DRUG

Active JNJ Drug

200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.

DRUG

Placebo pill

Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.

Trial Locations (1)

15213

Univ of Pittsburgh Medical Center, Pittsburgh

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Chengappa, K.N. Roy, MD

OTHER

NCT02217527 - Test of Novel Drug for Smoking Cessation | Biotech Hunter | Biotech Hunter